4-甲酰基-1,2,5-三甲基-1H-吡咯-3-羧酸甲酯 | 175276-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 4-甲酰基-1,2,5-三甲基-1H-吡咯-3-羧酸甲酯
• 英文名称: Methyl 4-formyl-1,2,5-trimethylpyrrole-3-carboxylate
• 英文别名: Methyl 4-formyl-1,2,5-trimethyl-1H-pyrrole-3-carboxylate
• CAS: 175276-49-0
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD00203864
• 分子量: 195.218
• InChiKey: NEDLMVCFWFSFNJ-UHFFFAOYSA-N

物化性质

• 熔点：
  124 °C
• 沸点：
  333.6±42.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	Methyl 4-formyl-1 2 5-trimethyl-1h-pyrrole-3-carboxylate 95+% Material Safety Data Sheet
Synonym:
CAS:	175276-49-0

Section 1 - Chemical Product MSDS Name:Methyl 4-formyl-1 2 5-trimethyl-1h-pyrrole-3-carboxylate 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175276-49-0	Methyl 4-formyl-1,2,5-trimethyl-1H-pyr	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175276-49-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 129 - 130 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H13NO3
Molecular Weight: 195.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175276-49-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 4-formyl-1,2,5-trimethyl-1H-pyrrole-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 175276-49-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175276-49-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175276-49-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲酰基-1,2,5-三甲基-1H-吡咯-3-羧酸甲酯 在 lithium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 生成 4-FORMYL-1,2,5-TRIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID
  参考文献：
  名称：

  Exploring a chemical encoding strategy for combinatorial synthesis using Friedel–Crafts alkylation

  摘要：

  使用铈(III)三氟乙酸盐和铽(III)三氟乙酸盐催化的Friedel–Crafts烷基化反应，在温和条件下将一组羟甲基吡咯酰胺标签（1b–i）引入聚苯乙烯树脂，同时展示了分裂混合肽库的编码过程。

  DOI：

  10.1039/a902489a

文献信息

• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS
  申请人：GLAXO GROUP LTD

  公开号：WO2013006596A1

  公开（公告）日：2013-01-10

  In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds,, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.

  一般而言，本发明涉及使用电压门控钠通道阻滞剂化合物，包括相应的前体、中间体、单体和二聚体，相应的药物组合物，化合物制备和治疗方法，用于呼吸和呼吸道疾病。具体而言，本发明还涉及用于治疗呼吸或呼吸道疾病的方法和用途，包括向需要的受试者施用本发明化合物的有效量。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20130023541A1

  公开（公告）日：2013-01-24

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.

  本发明涉及电压门控钠通道阻滞剂中间体、化合物和二聚体，相应的药物组合物、化合物制备和治疗呼吸或呼吸道疾病的方法。
• GANGLIOSIDE GD2 AS A MARKER AND TARGET ON CANCER STEM CELLS
  申请人：Board of Regents , The University of Texas System

  公开号：US20150044233A1

  公开（公告）日：2015-02-12

  Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.
• US9846160B2
  申请人：——

  公开号：US9846160B2

  公开（公告）日：2017-12-19
• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DE CANAUX SODIQUES SENSIBLES AU POTENTIEL
  申请人：GLAXO GROUP LTD

  公开号：WO2011088201A1

  公开（公告）日：2011-07-21

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.